A new cell therapy company has launched in Cambridge, UK, with $59 million in series A funding provided by Sofinnova Partners and others, including Sanofi Ventures.
A spin-out from the prestigious University of Cambridge, T-Therapeutics is also supported by the college’s own venture fund.
The money will be put towards the discovery and development of novel T cell receptor (TCR) therapeutics for cancer and inflammatory disorders.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze